SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Q2 Results 2026 (FY27): Revenue ₹316.08 Cr, PAT ₹40 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get SMS Pharmaceuticals Ltd's next results in your feed
Guidance rank: #42 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
SMS Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26.
As stated in SMS Pharmaceuticals Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on SMS Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6). Q2FY27 EBITDA: ₹68 crore, representing a 40% YoY increase (from ₹48 crore in Q2FY26).
From SMS Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did SMS Pharmaceuticals' revenue grow in the September 2026 quarter?
- Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6).
- H1FY27 revenue from operations: ₹523.05 crore, up 19% YoY from ₹438.48 crore in H1FY26 (Page 29, 7).
- Volume growth is cited as a driver for revenue growth alongside improved price realization (Page 5).
2 more points from SMS Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
What happened to SMS Pharmaceuticals' margins in Q2 FY27?
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is SMS Pharmaceuticals planning?
- Total capex of ₹280 crore planned to be completed by FY27 (Page 27).
- Capex oriented towards:
- Capacity expansion for existing APIs
- Building capacities for new API pipeline
- Land acquisition in process for a greenfield project (Page 27).
- Capex project mix: 89% brownfield, 11% greenfield (Page 27).
2 more points from SMS Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is SMS Pharmaceuticals raising money or cutting debt?
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is SMS Pharmaceuticals' order book?
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
- Zim Laboratories (Q2 FY27)
Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10). Key investor presentation takeaways from Zim Laboratories Ltd'
- Aurobindo Pharma (Q2 FY27)
Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13). Key investor presentation takeaways from Aurobindo Pharma Ltd's Q2 FY27 investor present
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q2 FY27 results?
Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6). Q2FY27 EBITDA: ₹68 crore, representing a 40% YoY increase (from ₹48 crore in Q2FY26).
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 48.1 with a market cap of ₹4,921 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Total capex of ₹280 crore planned to be completed by FY27 (Page 27).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.